(Total Views: 275)
Posted On: 08/27/2018 4:25:29 PM
Post# of 72440
It's being realistic rather than drinking kool-aid, so I don't understand why this is considered as bashing. Even if IPIX is sold for $500M to $750M, it's still a substantial amount of money for a portfolio of mere Phase 2 drugs. Similarly, if you are suggesting that IPIX will be a multi-billion company by so and so, isn't that constitute as manipulation as well, or worst, pumping?
Firstly, none of IPIX drugs are in Phase 3, so it needs money to fund the most expensive phase of the trial. Imagine you're Ehrlich or Bertolino going to a negotiation table with big pharma executives, what kind of leverage can you pull other than just phase 2 drugs with no cash at all? You can't go it alone and hamstrung by zero cash. So who's in a better negotiating position?
Secondly, IPIX has no clinical trials in active anymore, so what's their road map now. They even stopped the Ovarian cancer drug abruptly.
Thirdly, Menon is 70 years old now. By 2025, he's more than 75. He can't monetize his shares in IPIX unless there's a buyout. It also seems that his clinical lab company Kard has been winding down (they have took down the website as well).
Firstly, none of IPIX drugs are in Phase 3, so it needs money to fund the most expensive phase of the trial. Imagine you're Ehrlich or Bertolino going to a negotiation table with big pharma executives, what kind of leverage can you pull other than just phase 2 drugs with no cash at all? You can't go it alone and hamstrung by zero cash. So who's in a better negotiating position?
Secondly, IPIX has no clinical trials in active anymore, so what's their road map now. They even stopped the Ovarian cancer drug abruptly.
Thirdly, Menon is 70 years old now. By 2025, he's more than 75. He can't monetize his shares in IPIX unless there's a buyout. It also seems that his clinical lab company Kard has been winding down (they have took down the website as well).
(1)
(6)Scroll down for more posts ▼
